William Aird: Rethinking Hemolysis Classification
William Aird, Professor of Medicine at Harvard Medical School, posted on X:
“1/6
RETHINKING HEMOLYSIS CLASSIFICATION
I recently saw an incredibly rare but fascinating case of T-cell large granular lymphocytic (T-LGL)–mediated, DAT-negative hemolysis.
It prompted me to rethink how we classify hemolytic anemia and revise the schematic accordingly.
2/6
We usually divide hemolysis into immune and non-immune:
- Immune → antibody-mediated (autoimmune or alloimmune), DAT-positive
- Non-immune → mechanical, microangiopathic, infectious, toxic
That framework covers >99% of cases.
3/6
But what about the ultra-rare, cell-mediated form, when cytotoxic T or NK cells directly attack red cells or precursors?
- No antibodies.
- No complement.
- DAT-negative.
Mechanism: perforin/granzyme or Fas–FasL–mediated cytotoxicity.
4/6
These are not theoretical.
Occasional cases of LGL leukemia have shown evidence of direct, antibody-independent RBC destruction, essentially a cell-mediated immune hemolysis.
Vanishingly rare, but biologically fascinating.
5/6
So, I’ve updated the diagram.
Under “Immune hemolysis,” I’ve added a side branch:
“Cell-mediated (T/NK-cell cytotoxicity, DAT-negative)”
It’s a footnote in clinical reality but makes the schema more complete for those who enjoy a good hematologic deep dive.
6/6
If you teach or think about hemolysis, this nuance helps connect the adaptive (antibody-mediated) and cellular (cytotoxic) arms of immunity.
Sometimes the exceptions are what remind us how beautifully complex blood can be.”
Stay updated with Hemostasis Today.
-
Oct 23, 2025, 06:03Melanie Daniel: Wonderful Presentation on Emicizumab by Mickael Rosa at ECTH
-
Oct 22, 2025, 06:17We Will Continue to Raise Awareness and Remind Rveryone That Donating Blood Means Saving Lives - Yeolyan Hematology and Oncology Center
-
Oct 21, 2025, 06:59Samwel Mikaye: Polycythemia and the Risk of Blood Clots
-
Oct 21, 2025, 06:58Samuel Nweke: Interpreting D-Dimer Results
-
Oct 21, 2025, 05:20Ewa Fiorentino Rozek: APS - When “Unprovoked” Clots And Pregnancy Loss Connect
-
Oct 23, 2025, 06:48Omid Seidizadeh Shares Deep Molecular Modeling and Mechanistic Insights into Type 2A VWD
-
Oct 23, 2025, 06:45Mélanie Roussel on D-Dimer Thresholds for Diagnosis of Pulmonary Embolism
-
Oct 23, 2025, 06:28Ramya Ramakrishnan on IDA Association with Depression
-
Oct 23, 2025, 06:07Cedric Hermans: Von Willebrand Disease Diagnosis - From Complexity to Simplicity
-
Oct 23, 2025, 05:45Andrew Larry Frelinger III on Activation of Platelets in Flow Cytometry
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 21, 2025, 06:58Arno Nierich: How Caffeine Affects Red Blood Cells and Blood Storage
-
Oct 21, 2025, 06:43Could Gene Therapy Offer Lasting Quality of Life for People with Hemophilia B?
-
Oct 23, 2025, 06:52Louise Bannon: Thrilled to Witness The Incredible Reach of This Year's World Thrombosis Day!
-
Oct 23, 2025, 06:50Caitlin Raymond to Speak at The 11th Annual Bloodless Medicine and Surgery Society Conference
-
Oct 22, 2025, 10:46Conversation with Ferran Nadeu – Touch Haematology Future Leader 2025
-
Oct 22, 2025, 10:32Lynn Malec - The New Director of the CCBD and Pharmacy at Children's Wisconsin
-
Oct 22, 2025, 09:41Deanna Joseph: Feeling Inspired and Deeply Grateful After Attending the 2025 HTRS SEARCH Workshop